Published in Curr Opin Clin Nutr Metab Care on January 01, 2017
Vitamin D and osteosarcopenia: an update from epidemiological studies. Curr Opin Clin Nutr Metab Care (2017) 0.75
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum. Nephrol Dial Transplant (2009) 1.74
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum (2007) 1.65
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Outcome of the living kidney donor. Nephrol Dial Transplant (2012) 1.57
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause (2004) 1.57
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Strategies for the prevention of hip fracture. Am J Med (2003) 1.50
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Estimating glomerular filtration rate in Asian subjects: where do we stand? Kidney Int (2011) 1.47
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Arch Phys Med Rehabil (2005) 1.42
Is cystatin C useful for the detection and the estimation of low glomerular filtration rate in heart transplant patients? Transplantation (2007) 1.41
Aberrant results observed with four immuno-assays for total and free prostate-specific antigen (PSA) determination: a case-report. Clin Chem Lab Med (2011) 1.39
Measurement uncertainty of creatinine in low values: Another good reason not to use the MDRD formula with low creatinine values. Clin Biochem (2006) 1.38
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am (2008) 1.27
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage (2004) 1.25
Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf) (2011) 1.24
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res (2006) 1.20
A new tool in the field of in-vitro diagnosis of allergy: preliminary results in the comparison of ImmunoCAP© 250 with the ImmunoCAP© ISAC. Clin Chem Lab Med (2010) 1.19
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res (2003) 1.17
Quality of life in sarcopenia and frailty. Calcif Tissue Int (2013) 1.17
Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol (2011) 1.15
The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab (2014) 1.14
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother (2009) 1.10
[Vitamin D deficiency in elderly men living in urban areas, at home or in institutions]. Presse Med (2007) 1.09
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging (2007) 1.07
D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res (2005) 1.06
New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage (2005) 1.06
Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporos Int (2004) 1.05
GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis (2012) 1.05
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord (2008) 1.04
Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol (2004) 1.03
MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? BMC Nephrol (2010) 1.03
The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol (2002) 1.02
Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int (2004) 1.01
Normal reference values for glomerular filtration rate: what do we really know? Nephrol Dial Transplant (2012) 1.01
Development of a clinical assessment tool in identifying Asian men with low bone mineral density and comparison of its usefulness to quantitative bone ultrasound. Osteoporos Int (2004) 1.00
Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol (2006) 0.99
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.99
Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res (2007) 0.98
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin (2006) 0.97
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol (2008) 0.97
A multicentric evaluation of IDMS-traceable creatinine enzymatic assays. Clin Chim Acta (2011) 0.97
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin (2008) 0.96
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics (2011) 0.96
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res (2004) 0.96
Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum (2013) 0.95
Analytical study of three cystatin C assays and their impact on cystatin C-based GFR-prediction equations. Clin Chim Acta (2008) 0.95
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy (2010) 0.95
Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int (2008) 0.94
Detection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine. BMC Nephrol (2014) 0.94
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) 0.93
Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clin Exp Res (2004) 0.93
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health (2011) 0.92
Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease. BMC Nephrol (2013) 0.92
Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res (2008) 0.92
Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant (2013) 0.92
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcif Tissue Int (2010) 0.92
Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone (2008) 0.91
Validity and reliability of the French version of the STarT Back screening tool for patients with low back pain. Spine (Phila Pa 1976) (2014) 0.91
Comparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis. Osteoporos Int (2003) 0.90
Treatment of postmenopausal osteoporosis. BMJ (2005) 0.90
Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutr (2008) 0.90
Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate. J Nephrol (2014) 0.89
Are the creatinine-based equations accurate to estimate glomerular filtration rate in African American populations? Clin J Am Soc Nephrol (2011) 0.89
Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract (2014) 0.89
Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int (2003) 0.89
The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res (2012) 0.89
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone (2010) 0.88
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int (2011) 0.88
Enzymatic but not compensated Jaffe methods reach the desirable specifications of NKDEP at normal levels of creatinine. Results of the French multicentric evaluation. Clin Chim Acta (2013) 0.88
Osteoporosis and sarcopenia: two diseases or one? Curr Opin Clin Nutr Metab Care (2016) 0.87
Urinary NGAL measurement: biological variation and ratio to creatinine. Clin Chim Acta (2010) 0.87